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population. The aim of the study was to evaluate the
impact of skin diseases on health state utlilities in the 
population. METHODS: A postal survey was carried out
on a sample of the population 20–84 years of age (n =
8000) of the county of Uppland, Sweden. Information on
dermatological problems was obtained by self-report.
Rating Scale was used to measure health state utilities.
RESULTS: The response rate was 68% (5404 individu-
als). A large proportion (20.5%) reported dermatological
problems and/or use of topical dermatological drugs. Skin
disease was evenly distributed over age but was more fre-
quent among women (23.3%) than among men (17.3%).
Persons reporting dermatological problems also reported
lower health state utility than others, 0.807 as compared
to 0.836 (p < 0.001). Dermatological problems had an
independent and statistically signiﬁcant (p < 0.01) effect
on utility when age, gender, somatic and psychiatric
comorbidity were included in a multivariate analysis.
CONCLUSIONS: The study shows that skin disorders
are a considerable problem in the population, and that
they do cause a decrease in health state utility as mea-
sured by the Rating Scale (RS). The result of this study
emphasizes the need for further epidemiological studies
analysing health state utilities in relation to severity and
type of skin disease.
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OBJECTIVES: New therapies for the treatment of severe
sepsis are in development and estimates are required 
of treatment costs, annual incidence and the national
burden-of-illness. This study concerns the Netherlands.
METHODS: Cost data were collected for 100 patients
consecutively admitted to a general hospital ICU from
1998 to 2000 for treatment of a ﬁrst episode of severe
sepsis. Costs were limited to direct medical ICU costs
from a societal perspective and collected with an activity
based information system. Annual incidence was esti-
mated with a point-prevalence survey in Dutch ICU’s, col-
lecting the clinical information concerning all patients at
the ICU on a single day. Patients were regarded as severely
septic if infection was present, two or more SIRS criteria
were fulﬁlled and when there was at least one dysfunc-
tional organ system. RESULTS: Daily costs were esti-
mated to be log-normally distributed with a mean of
€1,244 ± 404. ICU length of stay was estimated to be geo-
metrically distributed with a mean of 15.3 ± 15.8 days.
Total treatment costs were estimated at €19,509 ± 26,966
(log-normal). Main cost items were ﬁxed costs (43%),
nursing costs (28%), diagnostic tests (7%), medication
(5%), renal replacement therapy (5%) and blood (4%).
The presence of shock and/or renal failure was signiﬁ-
cantly associated with higher treatment costs, whereas
ICU survival only showed a trend towards increase.
Forty-seven ICU’s participated in the prevalence survey
and 143 patients were found to meet the criteria for
severe sepsis. The national incidence was estimated at
8,643 ± 929 patients per year. CONCLUSIONS: Costs of
severe sepsis treatment within the ICU are estimated at
€168.6 ± €29.5 million per year. This equals 1.7% of the
national hospital budget and 0.51% of all healthcare
expenses in 2000 in the Netherlands.
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OBJECTIVES: To determine and compare costs and cost
driving factors in the management of severe sepsis either
within a clinical trial setting or in daily practice.
METHODS: One hundred ﬁfty-two patients (from 4
Belgian centres) fulﬁlling criteria for severe sepsis between
1998 and 2000 were included in a chart review. Ninety-
one were clinical trial patients (rhAPC, TFPI or ATIII);
61 were non-trial patients. All healthcare costs (payers
perspective) between sepsis diagnosis and discharge were
collected from patient invoices by independent
researchers. RESULTS: Trial and non-trial patients were
comparable with regard to age, status (medical or surgi-
cal), underlying conditions including COPD, alcohol or
tobacco abuse and immunosuppression. Differences were
observed in mortality (45% versus 50%, trial versus non-
trial patients respectively), positive blood cultures (39%
versus 75%), renal replacement therapy (22% versus
31%), hypertension (41% versus 31%) cardiomyopathy
(16% versus 29%) cerebrovascular disease (5% versus
13%) and malignancy (19.8% versus 8%). There was no
difference (trial versus non-trial) in hospital (28 versus 27
days) or ICU length of stay (16 days both) after sepsis
diagnosis. Overall costs were similar in trial and non-trial
patients: €19,292 (St E:1,574) versus €16,314 (St E:
1,684) respectively. Multivariate regression (OLS on log-
transformed cost) revealed the following explaining
factors for total cost: death (neg. p = 0.003), pos. blood
culture (pos. p = 0.009), university hospital (pos. p =
0.035), mechanical ventilation (pos. p = 0.002) and renal
replacement therapy (pos. p = 0.002). The variable “trial
patient or not” revealed a p-value of 0.624. CONCLU-
SIONS: Factors inﬂuencing costs in severe sepsis include
death, pos. blood culture, university hospital setting,
renal replacement therapy and ventilation. Trial and non-
trial patients appear to be comparable with regard to
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medical resource use and total costs, after adjustment for
baseline characteristics. Such observations are of rele-
vance in the interpretation of economic evaluation results,
and should be assessed in different disease areas.
PIN3
THE TREATMENT OF SEPSIS PATIENTS WITH
DROTRECOGIN ALFA (ACTIVATED):AN
ECONOMIC EVALUATION WITH REFERENCE 
TO ITALY
Lucioni C1, Guidi L2, Mazzi S1, Chinn C3,The PROWESS ET4
1ADIS International, Milano, Italy; 2Eli Lilly, Sesto Fiorentino,
Firenze, Italy; 3European Health Outcomes Research, Lilly,
Windlesham, Surrey, United Kingdom; 4Care of Eli Lilly & Co
Ltd, Indianapolis, IN, USA
OBJECTIVE: An international phase III trial (PROWESS,
N = 1690) assessed that treatment with drotrecogin alfa
(activated) reduced 28-day mortality among patients with
severe sepsis. In the present study, cost effectiveness
analyses are performed of this therapy in the treatment
of severe sepsis (SS) and severe sepsis with multiple organ
failure (SS/MOF) in Italy. METHODS: A decision model
was developed based on PROWESS outcomes and
resource use information. Absolute reduction in hospital
mortality at day 28 was 6.0% (7.3% for patients with 2
or more organ dysfunctions at baseline (N = 1271)). Italy-
speciﬁc cost data were applied to the resource use pat-
terns of the European trial patients. Hospitalisation costs
were based on published full daily cost estimates for ICU
(€1,033) and the regular ward (€300). Assumed drotre-
cogin alfa (activated) cost in Italy is €261 per 5mg vial,
including VAT. Placebo arm cost of standard care includes
€1,580 for Anti-thrombin III (ATIII) which is often used
for treatment of sepsis patients in Italy but which has not
shown a reduction in mortality in major trials (7,392U
ATIII per patient at €381 per 1,000U (for 56% patients
(from an expert panel)). Italian Life Tables were used to
estimate life expectancy; which was adjusted for effects
of severe sepsis. RESULTS: The estimated incremental
cost per life year gained for drotrecogin alfa (activated)
is €13,436 for SS (€17,148 discounting life years at 3%)
and for SS/MOF is €9,660 (€12,284). CONCLUSIONS:
A rule-of-thumb maximum acceptable value for a life year
gained is about €50,000. Another suggested standard, the
per capita GDP, would be about €20,000 for Italy. Both
such amounts by far exceed the amount here reported for
drotrecogin alfa (activated), which appears to be cost
effective for the treatment of patients with severe sepsis,
and severe sepsis with multiple organ failure, in Italy.
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OBJECTIVES: In the PROWESS trial (n = 1690),
drotrecogin alfa (activated) (recombinant human Acti-
vated Protein C) signiﬁcantly decreased the 28-day mor-
tality in adults with severe sepsis compared with placebo
(ARR 6,1%; p = 0,005). A cost-effectiveness analytical
model was conducted to assess the efﬁciency of the drug
in Spain in the trial population and in the expected
approved indication (patients with multiple organ fail-
ures). METHODS: National Health Service perspective
was used in the analysis. Effectiveness and resource use
were obtained from data collected prospectively in the
trial. Spanish costs data of patients treated in intensive
care were applied. Direct costs assessed were drug 
cost, costs up to 28 days, and to ﬁnal discharge. Life
expectancy was estimated using actual age and sex, and
Spanish life tables, and an adjustment for post discharge
mortality associated with severe sepsis. Cost per hospital
survivor and incremental hospital cost per life year gained
(LYG) were calculated. LYG were not discounted in the
base case analysis. Sensitivity analysis was applied adjust-
ing for patterns of care, ICU costs, comorbidity and dis-
count rate. RESULTS: In patients with multiple organ
failure, drotrecogin alfa (activated) saved 7.3 additional
lives in hospital per 100 treated patients at 28 days when
compared with placebo (p < 0,05) (NNT = 14). The cost
per hospital survivor was €119,857. Hospital survivors
were estimated to live 12.2 years. The cost-effectiveness
of drotrecogin alfa (activated) was €9,799 per LYG when
compared with placebo (€13,594 per LYG for the trial
population). The sensitivity analysis indicated that the
largest inﬂuence on costs were the assumptions of the dis-
count and reduction in life expectancy of patients. CON-
CLUSIONS: In Spain, drotrecogin alfa (activated) has
shown to be efﬁcient in the treatment of severe sepsis. The
incremental CE is better than many well-accepted and
common healthcare interventions.
